Bank of America Securities analyst Travis Steed reiterated a Sell rating on Embecta Corporation (EMBC – Research Report) yesterday and set a price target of $25.00. The company’s shares closed yesterday at $21.50.
Steed covers the Healthcare sector, focusing on stocks such as Boston Scientific, Baxter International, and Becton Dickinson. According to TipRanks, Steed has an average return of 9.3% and a 60.00% success rate on recommended stocks.
Embecta Corporation has an analyst consensus of Moderate Sell, with a price target consensus of $22.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $36.06 and a one-year low of $19.52. Currently, Embecta Corporation has an average volume of 585.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Read More on EMBC:
